This product is a semi-synthetic aminoglycoside antibiotic with strong antibacterial activity and a broad antibacterial spectrum. It has high antibacterial activity against Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Citrobacter, Proteus (indole-positive and indole-negative), Salmonella, Shigella, Haemophilus influenzae, etc. It is also highly sensitive to certain species of bacteria such as Pseudomonas aeruginosa, Mycobacterium tuberculosis, Providencia and Acinetobacter. It has antibacterial activity against most Staphylococci, including methicillin-sensitive strains. It mainly acts on the ribosomes in bacteria, inhibits the synthesis of bacterial proteins, and has a strong bactericidal effect.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial effect on most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good resistance to Chlamydia trachomatis, Mycoplasma and Legionella.

The specific pharmacological effects are not clearly mentioned in the information

Edaravone is a brain protectant (free radical scavenger) that can scavenge free radicals and inhibit lipid peroxidation, thereby inhibiting oxidative damage to brain cells, vascular endothelial cells, and nerve cells. Preclinical studies have shown that edaravone can prevent the progression of cerebral edema and cerebral infarction, relieve the accompanying neurological symptoms, and inhibit delayed neuronal death.

Inhibits the production of malondialdehyde and thromboxane B2, reduces myocardial edema and the release of lactate dehydrogenase, and promotes the production of 6-keto-prostaglandin F1α, which has the effects of anti-platelet aggregation, vasodilation and myocardial protection.